P2s: Practice-changing, Paradigm-shifting Clinical Trials in Urology

About the Program

Practice-changing, Paradigm-shifting Clinical Trials in Urology (P2s) are designed to showcase the exceptional, groundbreaking studies that are expected to change the day-to-day practice of urology. Reserved for the most impactful studies, P2s will be presented on the Plenary stage, providing the greatest exposure and profile for the research.

Eligible Studies

The AUA is looking for studies that address scientific questions of particular interest to urologists. Studies should include primary data using:

1. A randomized clinical trial design (phase II or III trials)
   OR
2. Prospective, observational cohort studies that compare therapies and/or highlight novel and high-impact interventions that will change clinical practice

Retrospective studies, basic science studies, meta-analyses, survey research, and/or case series and reports are NOT appropriate for submission.

Policies

AUA membership is not required for submission.

Prior to the AUA Annual Meeting, the contents and conclusions of the submission must not have been presented at or published in conjunction with any scientific, medical, or educational meeting with the following exceptions:

• Abstracts previously accepted to AUA Sectional meetings or select urologic sub-specialty societies are eligible for submission even if presented or published under the scientific, medical, or educational outlets of those meetings. Authors are strongly encouraged to provide updated data in the abstract submitted to the AUA Annual Meeting.
• Study results may be presented at closed (non-public) meetings under the condition that no meeting materials are publicly disseminated in any format.

In addition, the contents and conclusions of the submission must not be published as a full-length research article in a scientific, medical, or educational publication (in any medium), in whole or in part, before it is published online by the AUA. Full-length pre-prints (non-peer-reviewed research articles published online for public dissemination and public comments are permitted before the abstract is submitted.

Any violation of these policies may subject the abstract to rejection or removal from the AUA Annual Meeting.

The Program Committee has the authority to reject submissions that are incomplete, deemed purely for marketing purposes, and/or written in a language other than English. Duplicate submissions by the same authors and based on the same study population or data will also be rejected.

Submission Requirements

The submission of a "shell" abstract is not required.

Authors

• Required fields for each author: First name, last name, email address, affiliation, city, state (U.S. only), and country. The submitting author must provide a unique email address belonging to each author.
• Do not include credentials (i.e., MD, PhD) in the name field.
• Though not required, please include the AUA ID for each author who has one.
• One author must be designated as the presenting author. The presenting author cannot be an employee of or have a financial relationship with the commercial interest that controls the content of the study or presentation.

Title

The title should clearly define the topic and contain no abbreviations. For professional consistency, titles must be in sentence case and not bolded, underlined, italicized, or written in all caps or lowercase letters. Titles are limited to 255 characters, including spaces.

The AUA will ensure abstract titles are properly formatted for the various publications including The Journal of Urology®.

Body

The text is limited to 2,280 characters, not including spaces. It is optional to include a maximum of two figures or graphics. Each figure or graphic counts as 225 characters.

Studies should present prospective, original research that highlight novel and high-impact research with practice-changing implications.

The body must be informative and detailed. The following sections are required:

• Introduction and objectives
• Methods
• Results
• Conclusions
• Source of funding – This field is required for submission. Authors must fully disclose all funding sources. If there is no support, please list "None".

The AUA recognizes that, particularly in the case of large Phase 3 studies, analysis may not be completed by the submission deadline. If this is the case, please make note in the conclusions section. During submission, you will be required to enter the background and methods sections, and provide the primary clinical endpoint for analysis, type of analysis, date of planned analysis, and planned statistical methods.

Those selected for presentation will be required to provide the final data set and analyses two weeks before the Annual Meeting.

Disclosures

Prior to participating in educational programs, presenters must disclose all financial relationships with ACCME-defined ineligible companies existing within the past 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The AUA COI Review Work Group will make a determination of which relationships are relevant and require mitigation.

Presenters are not permitted to have financial relationships with ineligible companies (formerly commercial interests) that the ACCME would deem to be that of an owner or employee. Owners are defined as individuals who have an ownership interest in a company, except for stockholders of publicly traded companies, or holders of shares through a pension or mutual fund. Employees are defined as individuals hired to work for another person or business (the employer) for compensation and who are subject to the employer's direction as to the details of how to perform the job.

Withdrawal Requests

The submitting author may return to the submission site to delete their submission at any time before 11:59 p.m. ET on February 16. After this date, requests to withdraw a submission must be sent to speakers@AUAnet.org. Please include the submission number, title, and reason for withdrawal. All co-authors must be copied on the communication. Requests which do not include all authors will not be processed.

Accepted Submissions

Submissions accepted for the Annual Meeting are copyrighted by the American Urological Association and published in a supplement of The Journal of Urology® on the first day of the Annual Meeting. No part of materials published in The Journal of Urology® may be reproduced without written permission of the publisher.

For information on requesting permission to reuse The Journal of Urology®, visit shop.lww.com/journal-permission or email publications@AUAnet.org.

Communications

During submission, AUA staff are authorized to communicate only with the presenting or corresponding author. Notifications regarding the outcome of a submission will be sent to the presenting author. After acceptance, AUA staff will communicate only with the presenting author regarding any matters, including withdrawal requests, which must be submitted in writing. Any queries or requests from co-authors or non-authors, including pharmaceutical companies or medical communications companies, must go through the presenting author. Any attempts to contact AUA directly by such individuals will not be responded to.

To ensure that you receive email notifications from AUA regarding your submission, please add AUA@mirasmart.com and speakers@AUAnet.org to your safe senders list.

Contact

Technical questions and submission issues can be sent to AUA@mirasmart.com. You may also call the Mira Tech Support line at (866) 341-9590 between the hours of 8 a.m. and 5 p.m., Central Time (14:00 to 23:00 GMT), Monday through Friday.

Please note, Mira is the abstract vendor and can only assist with technical submission questions and issues.

All other questions related to the submission process can be sent to speakers@AUAnet.org.